Krystal Biotech (KRYS) continues to face significant short-selling pressure, maintaining its position on the FINRA Reg SHO threshold list for 77 consecutive days. The stock currently carries a short interest of 13.7% of the float. Despite the high volume of short activity, the borrow fee remains relatively stable at 0.3%, suggesting that while the stock is heavily shorted, there is currently sufficient supply in the lending market to meet demand. However, the sustained threshold status warrants caution, as it indicates that short sellers are consistently failing to deliver shares, which can lead to forced buy-ins if regulatory scrutiny intensifies.
Signal data sourced from Tapeboard. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.